46 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
2 Nov 22
Report of Foreign Private Issuer
7:19am
and the Physician Global Assessment (PGA) response index calculated based on the Erythema + Infiltration + Desquamation. The study further showed that in patients
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
12 Sep 22
Report of Foreign Private Issuer
7:02am
of subjects who achieve, respectively, PASI 50, Physician Global Assessment (PGA) score of 0 or 1, and improvement on the Psoriasis Disability Index (PDI
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
22 Aug 22
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
7:05am
Assessment (PGA) score of 0 or 1, and improvement on the Psoriasis Disability Index (PDI) at Week 16 (superiority); evaluate the efficacy of oral
6-K
EX-99.1
tar9 rfyt2
11 Jul 22
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
7:13am
6-K
EX-99.1
ep57ickn3ftp3
29 Jun 22
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORTTM Study in Moderate to Severe Psoriasis
7:09am
424B3
7dxkrcwygdyn9wf1bi
1 Jun 20
Prospectus supplement
7:23am
6-K
EX-99.2
ezrr1oht m8koy2m4w
1 Jun 20
Report of Foreign Private Issuer
7:06am
6-K
EX-99.1
xk7tos0qq2uywc1chu
1 Jun 20
Report of Foreign Private Issuer
7:06am
424B4
vuzo9
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
hz3xsfje84c67j v9bx8
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
1fqwxugl2yhkvbom
24 Jan 20
Registration statement (foreign)
4:40pm
6-K
EX-99.1
hrl0wnoob
3 Jun 19
Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session
7:09am
6-K
EX-99.1
vpjvqsmsld9b ini
10 Apr 19
Report of Foreign Private Issuer
7:13am
20-F/A
svdywid5dla0iva3 rqe
2 Apr 19
Annual report (foreign) (amended)
6:52am